140 related articles for article (PubMed ID: 32488332)
21. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
Uotani T; Sugimoto M; Nishino M; Kodaira C; Yamade M; Sahara S; Yamada T; Osawa S; Sugimoto K; Tanaka T; Umemura K; Watanabe H; Miyajima H; Furuta T
Clin Gastroenterol Hepatol; 2012 Aug; 10(8):879-885.e2. PubMed ID: 22542748
[TBL] [Abstract][Full Text] [Related]
22. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Shimatani T; Inoue M; Kuroiwa T; Horikawa Y
Aliment Pharmacol Ther; 2004 Jan; 19(1):113-22. PubMed ID: 14687173
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
24. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.
Nuki Y; Umeno J; Washio E; Maehata Y; Hirano A; Miyazaki M; Kobayashi H; Kitazono T; Matsumoto T; Esaki M
Aliment Pharmacol Ther; 2017 Aug; 46(3):331-336. PubMed ID: 28481007
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
26. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.
Toda R; Shiramoto M; Komai E; Yoshii K; Hirayama M; Kawabata Y
J Clin Pharmacol; 2018 Apr; 58(4):425-433. PubMed ID: 29193126
[TBL] [Abstract][Full Text] [Related]
29. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Uotani T; Sugimoto M; Nishino M; Ichikawa H; Sahara S; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
J Clin Pharmacol; 2014 Aug; 54(8):858-64. PubMed ID: 24615745
[TBL] [Abstract][Full Text] [Related]
30. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
31. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
32. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
[TBL] [Abstract][Full Text] [Related]
33. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
34. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
35. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
36. Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression.
Furuta K; Adachi K; Aimi M; Shimura S; Mikami H; Nishimura N; Ishimura N; Ishihara S; Naora K; Kinoshita Y
Digestion; 2016; 93(2):111-20. PubMed ID: 26637113
[TBL] [Abstract][Full Text] [Related]
37. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T
Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512
[TBL] [Abstract][Full Text] [Related]
38. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
39. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Sugimoto M; Nishino M; Kodaira C; Yamade M; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
J Clin Pharmacol; 2010 Mar; 50(3):320-30. PubMed ID: 19940233
[TBL] [Abstract][Full Text] [Related]
40. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
